Short answer
Revolution Medicines Inc (RVMD) filed an 8-K current report with the SEC on August 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results announced for quarter ended June 30, 2026.
Revolution Medicines Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results announced for quarter ended June 30, 2026
- Full earnings release furnished as Exhibit 99.1, containing detailed operating and financial results
- Results announcement provides investors the company’s latest quarterly performance update
Item EX-99.1 · Exhibit EX-99.1
- FDA accepted daraxonrasib’s NDA for previously treated metastatic pancreatic cancer, advancing the lead program toward potential commercialization
- Expanded Access Program reached more than 2,000 patients across nearly 50 U.S. states and Puerto Rico, signaling substantial physician and patient demand
- Cash, equivalents and marketable securities totaled $3.9 billion, supported by $2,225.0 million of April financing and a $250.0 million Royalty Pharma payment
- Second-quarter R&D expenses rose to $394.9 million and G&A to $110.2 million, reflecting late-stage trials and commercial launch preparation
- Net loss widened to $644.4 million, including a $151.0 million non-cash warrant fair-value charge; 2026 GAAP operating expense guidance increased to $2.1-$2.2 billion
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Revolution Medicines Inc 8-K filings
Get the next RVMD 8-K as it lands
Follow RVMD for push alerts, or ask the research agent what this filing means.